Deutsche Bank
http://www.db.com/
Deutsche Bank is a leading global investment bank with a strong and profitable private clients franchise.
The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM) and Corporate Investments (CI) . The CIB division engages in the origination, sale, financing, structuring, and trading of fixed income, equity, equity-linked, convertible bond, foreign exchange, and commodities products. The PCAM segment provides portfolio/fund management products, including active fund management, passive/quantitative fund management, alternative investments, and discretionary portfolio management solutions in Germany and other continental European countries.-
Deutsche Bank Maintains a 'Hold' on Genzyme (GENZ); Genetics Sale-More Upside if Diagnostics Sold
-
Notable Analyst Rating Changes 09/03: BKE, KSP, DRIV, LAYN Upgraded; MITL, BKC, TTWO, AEO Downgraded
-
Wall Street Hubbub 8/16: 13F Season, 3Par/Dell Deal Sparks Chatter, What About Genzyme?
-
Deutsche Bank Starts Genzyme (GENZ) at Hold, Sees Sanofi Deal Getting Done
-
Genzyme (GENZ) volatility elevated on uncertainty of deal
-
Notable Analyst Rating Changes 06/01: LVS, GENZ, V, CPT Upgraded; CNK, BEAT, GLW, AEO Downgraded
-
Notable Analyst Rating Changes 03/25: GGB, NKE, EBAY, TAP, WERN Upgraded; BRCD, NLY, SBUX, MELA, GENZ Downgraded
-
Notable Analyst Rating Changes 12/03: BAC, BKD, AVB, THC, RIG Upgraded; KIM, GENZ, REG, TCK Downgraded
-
FDA Warns Doctors of Contamination at Genzyme (GENZ) Plant; Stock Tumbles
-
Deutsche Bank Says Genzyme (GENZ) FDA Warning May Not Be a Big Deal
-
Notable Analyst Rating Changes 9/24: MTH, NSM, WFC, AIMC, CPN, SHFL Higher; LLL, AZN, VIP, ANN, KGC, UFS Downgraded
-
Notable Analyst Rating Changes 9/18: ETFC, SNDK, TOL, SBUX, PG, AMED Upgraded; SCHW, GENZ, MDC, IMAX, MOT Downgraded
-
Deutsche Bank Downgrades Genzyme (GENZ) to Hold; Risk/Reward Balanced
-
David Moenning’s Daily State of the Markets: 6/26
-
David Moenning's Daily State of the Markets: 5/20
-
Morning Movers 5/20: TWB, PRGN, PNX, IRE, WPCS, IGLD Higher; RBC, ONTY, ISIS, HTZ Lower
-
Notable Analyst Rating Changes 3/27: AMGN, COP, JCP, UPS, CAG, CPWR Upgraded; FSLR, PBR, UTIW, STP, BHP Downgraded
-
Morning Movers 3/9: Schering-Plough (SGP) Higher On Merck (MRK) Merger, Stem Cell Stocks Rock On Obama Move To Lift Funding Restrictions
-
Notable Analyst Rating Changes 3/9: KO, AMZN, BBY, GENZ Upgraded; PBR, BBD, AFL Downgraded
-
Deutsche Bank Upgrades Genzyme (GENZ) to Buy; Myozyme Delays Create Buying Opportunity
-
David Moenning's Daily State of the Markets: 3/6
-
Deutsche Bank Comments on Genzyme (GENZ) Related to FX Exposure
-
Notable Analyst Rating Changes 9/8: GS, AMD, RIMM, NLY Upgraded; AZO, NOK, RFMD, GSK Downgraded
-
David Moenning's Daily State of the Markets: 7/23
-
David Moenning's Daily State of the Markets: 7/14
-
Notable Analyst Rating Changes 7/14: NOV, AA, GENZ, M Upgraded; UAUA, ZION, HOT, DB Downgraded
-
Deutsche Bank Starts Genzyme (GENZ) at Hold
-
Deutsche Bank Starts Coverage on Large Biotechs; DNA, GILD & AMGN Rated Buys, BIIB & GENZ Rated Holds
